What Legal Duty Do Practitioners Have to Warn Potential Victims of a Patient?
Two years after her husband was killed, Mr Z’s grandmother sued several of the hospital’s physicians.
Psychosis
Rexulti Approval Expanded to Include Adolescents With Schizophrenia
The approval was based on data from an ongoing phase 3 trial evaluating the safety and tolerability of brexpiprazole as maintenance treatment of 194 patients aged 13 to 17 years with schizophrenia.
Lybalvi Now Available for Schizophrenia, Bipolar I Disorder
Lybalvi is an atypical antipsychotic comprised of samidorphan co-formulated with olanzapine in a single bilayer tablet.
Drug Therapy for Borderline Personality Disorder Evaluated
While no drugs are currently approved for the treatment of BPD, nearly all patients with this condition receive at least 1 psychotropic medication.
Invega Hafyera Approved for Twice-Yearly Treatment of Schizophrenia
The Food and Drug Administration has approved Invega Hafyera™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting atypical antipsychotic that is administered as a gluteal intramuscular injection by a health care professional. Prior to initiating treatment with Invega Hafyera, patients must have been adequately treated…
Application for Long-Acting Schizophrenia Treatment Accepted for Review
Patients treated with the investigational subcutaneous risperidone injection experienced a statistically significant delay in the time to relapse.
Lyme Disease Tied to Higher Risk for Psychiatric Conditions, Suicide
Risk particularly heightened in the six months following diagnosis
Important Clozapine REMS Program Changes Announced
According to the FDA, prescribers and pharmacies must be re-certified in the Clozapine REMS program by November 15, 2021 to continue to prescribe or dispense clozapine.
Relapse Risk for Psychosis in Dementia Lower With Continued Pimavanserin
Findings seen in double-blind, randomized, placebo-controlled discontinuation trial that was stopped early for efficacy
Lybalvi Approved for Schizophrenia, Bipolar I Disorder
The approval was based on data from 27 clinical studies, including the phase 3 ENLIGHTEN-1 and ENLIGHTEN-2 studies.
